Trichostatin A-treated eight-cell bovine embryos had increased histone acetylation and gene expression, with increased cell numbers at the blastocyst stage

Trichostatin A-treated eight-cell bovine embryos had increased histone acetylation and gene expression, with increased cell numbers at the blastocyst stage
复制标题

DOI:
10.1016/j.theriogenology.2010.10.026
复制
发表时间:
2011-03-15
期刊:
影响因子:
2.8
通讯作者:
Kuwayama, Takehito
Kuwayama, Takehito
中科院分区:
农林科学2区
文献类型:
--
作者:
Shiratsuki, Shogo;Iwata, Hisataka;Kuwayama, Takehito

文献摘要

被引文献

相似文献

目的是确定一种有效的组蛋白脱乙酰酶抑制剂曲古抑素A(TSA)对8细胞牛胚胎的影响。抗AcH4K5和AcH4K8抗体的免疫组织化学染色证实,该治疗增加了组蛋白乙酰化。TSA(100 NM)处理不同时间间隔(4、8和12h)的胚胎发育到囊胚期的频率与未处理的胚胎相同(平均发育率为49.5%)。TSA处理12h后,囊胚内细胞团(ICM)细胞数、细胞总数(TC)及ICM/TC比值增加(P<0.05),滋养外胚层细胞数减少(P<0.05)。处理组胚胎的Oct3/4和E-cadherin的相对丰度(RA)显著高于对照组(P<0.05),而CDX2的相对丰度(RA)无明显变化。综上所述,TSA处理的8-细胞期胚胎增加了组蛋白乙酰化和基因表达,增加了ICM数和TC数,增加了ICM/TC比值,但显著减少了滋养外胚层中的细胞数。(C)2011 Elsevier Inc.保留所有权利。
The objective was to determine the effects of trichostatin A (TSA), a potent histone deacetylase inhibitor, on eight-cell bovine embryos. That treatment increased histone acetylation was confirmed by immunostaining with anti-AcH4K5 and AcH4K8 antibodies. Embryos treated with TSA (100 nM) for various intervals (4, 8, and 12 h) developed to the blastocyst stage as frequently as untreated embryos (average development rate, 49.5%). Treatment with TSA for 12 h increased (P < 0.05) the numbers of inner cell mass (ICM) cells and total cells (TC), as well as the ICM/TC ratio in the blastocyst, but the number of cells in the trophectoderm decreased (P < 0.05). Treated embryos had increased relative abundance (RA) of OCT3/4 and E-CADHERIN mRNA relative to controls at the morula stage (P < 0.05), however, the RA of CDX2 mRNA was unchanged. In conclusion, TSA-treated eight-cell stage embryos had increased histone acetylation and gene expression, which increased ICM and TC numbers and the ICM/TC ratio, but significantly decreased the number of cells in the trophectoderm of resulting blastocysts. (C) 2011 Elsevier Inc. All rights reserved.